IL151527A0 - Mutated cyclyn g1 protein - Google Patents

Mutated cyclyn g1 protein

Info

Publication number
IL151527A0
IL151527A0 IL15152701A IL15152701A IL151527A0 IL 151527 A0 IL151527 A0 IL 151527A0 IL 15152701 A IL15152701 A IL 15152701A IL 15152701 A IL15152701 A IL 15152701A IL 151527 A0 IL151527 A0 IL 151527A0
Authority
IL
Israel
Prior art keywords
protein
mutated
animal
cyclyn
administering
Prior art date
Application number
IL15152701A
Other languages
English (en)
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of IL151527A0 publication Critical patent/IL151527A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15152701A 2000-03-02 2001-03-01 Mutated cyclyn g1 protein IL151527A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51783200A 2000-03-02 2000-03-02
PCT/IB2001/000303 WO2001064870A2 (en) 2000-03-02 2001-03-01 Mutated cyclin g1 protein

Publications (1)

Publication Number Publication Date
IL151527A0 true IL151527A0 (en) 2003-04-10

Family

ID=24061405

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15152701A IL151527A0 (en) 2000-03-02 2001-03-01 Mutated cyclyn g1 protein
IL151527A IL151527A (en) 2000-03-02 2002-08-28 Mutated cyclin g1 protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151527A IL151527A (en) 2000-03-02 2002-08-28 Mutated cyclin g1 protein

Country Status (10)

Country Link
EP (1) EP1259605B1 (ja)
JP (2) JP2003525607A (ja)
AT (1) ATE362535T1 (ja)
AU (3) AU2001234025B2 (ja)
CA (1) CA2401545C (ja)
DE (1) DE60128445T2 (ja)
ES (1) ES2287098T3 (ja)
IL (2) IL151527A0 (ja)
NZ (1) NZ521070A (ja)
WO (1) WO2001064870A2 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
DE10157454B4 (de) * 2001-11-23 2005-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum Erzeugen einer Kennung für ein Audiosignal, Verfahren und Vorrichtung zum Aufbauen einer Instrumentendatenbank und Verfahren und Vorrichtung zum Bestimmen der Art eines Instruments
JP2006524057A (ja) * 2003-04-21 2006-10-26 エペイウス バイオテクノロジーズ， インコーポレイテッド 疾患を処置するための方法および組成物
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
JP5892666B2 (ja) * 2014-03-14 2016-03-23 国立大学法人大阪大学 細胞死促進剤
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724439B2 (en) * 1995-11-01 2000-09-21 University Of Southern California Expression of cyclin G1 in tumours

Also Published As

Publication number Publication date
ATE362535T1 (de) 2007-06-15
EP1259605A2 (en) 2002-11-27
WO2001064870A2 (en) 2001-09-07
AU2008221564A1 (en) 2008-10-16
CA2401545C (en) 2011-01-04
CA2401545A1 (en) 2001-09-07
AU2001234025B2 (en) 2005-07-07
DE60128445T2 (de) 2008-01-10
JP2011160815A (ja) 2011-08-25
EP1259605B1 (en) 2007-05-16
ES2287098T3 (es) 2007-12-16
DE60128445D1 (de) 2007-06-28
NZ521070A (en) 2004-07-30
WO2001064870A3 (en) 2002-01-31
IL151527A (en) 2010-12-30
AU3402501A (en) 2001-09-12
JP2003525607A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
HK1103363A1 (en) Treatment of glycogen storage diseases type ii ii
SI1641483T1 (sl) Fuzijski proteini
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
EP1381280A4 (en) VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
AU2904300A (en) Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
IL151527A (en) Mutated cyclin g1 protein
AU2225199A (en) Human suppressor trna oligonucleotides and methods of use for same
AU2290000A (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
DE60034879D1 (en) Lantibiotikum
SI1465927T1 (sl) Protitelesa proti BAG3 za uporabo pri raziskavi, diagnostiki in terapiji bolezni, ki vključujejo celično smrt
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
EP1449431A4 (en) NON-HUMAN ANIMAL GENETICALLY MODIFIED SRGF ANIMAL
WO2002087612A3 (de) Verwendung von stimulierten mononukleären zellen des peripheren blutes zur behandlung von krebserkrankungen
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
WO2000004153A3 (en) Repression of cell transformation with human pea3
PL370854A1 (en) Ee3-protein family and corresponding dna sequences